- Home
- FEBO vs NERV Comparison
FEBO vs NERV Comparison
Compare FEBO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- NERV
- Stock Information
- Founded
- FEBO 1993
- NERV 2007
- Country
- FEBO Hong Kong
- NERV United States
- Employees
- FEBO 271
- NERV N/A
- Industry
- FEBO
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- NERV Health Care
- Exchange
- FEBO Nasdaq
- NERV Nasdaq
- Market Cap
- FEBO 21.9M
- NERV 18.3M
- IPO Year
- FEBO 2023
- NERV 2014
- Fundamental
- Price
- FEBO $2.00
- NERV $2.19
- Analyst Decision
- FEBO
- NERV Hold
- Analyst Count
- FEBO 0
- NERV 1
- Target Price
- FEBO N/A
- NERV $5.00
- AVG Volume (30 Days)
- FEBO 55.5K
- NERV 25.4K
- Earning Date
- FEBO 11-29-2024
- NERV 11-05-2024
- Dividend Yield
- FEBO N/A
- NERV N/A
- EPS Growth
- FEBO N/A
- NERV N/A
- EPS
- FEBO N/A
- NERV N/A
- Revenue
- FEBO $16,319,897.00
- NERV N/A
- Revenue This Year
- FEBO N/A
- NERV N/A
- Revenue Next Year
- FEBO N/A
- NERV N/A
- P/E Ratio
- FEBO N/A
- NERV N/A
- Revenue Growth
- FEBO 9.01
- NERV N/A
- 52 Week Low
- FEBO $1.68
- NERV $2.07
- 52 Week High
- FEBO $17.68
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- FEBO 33.32
- NERV 41.39
- Support Level
- FEBO $1.68
- NERV $2.08
- Resistance Level
- FEBO $3.01
- NERV $2.35
- Average True Range (ATR)
- FEBO 0.41
- NERV 0.10
- MACD
- FEBO -0.04
- NERV -0.00
- Stochastic Oscillator
- FEBO 25.89
- NERV 40.92
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.